IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Status: Recruiting
Phase: Phase 1
Diagnosis: Non-Hodgkin's Lymphoma
NCT ID: NCT01534715 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-279

 

The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).

 

Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital

Overall PI:
Arnold Freedman, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Kathleen McDermott, kmcdermott@partners.org

Eligibility Criteria

Inclusion Criteria: - Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL). - Adequate organ function - ECOG ≤ 2 - Recovered or stabilized from prior treatments. Exclusion Criteria: - Allogeneic stem cell transplantation - Pregnant or lactating females - Known central nervous system, meningeal or epidural disease including brain metastases
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms